International Swiss medtech continues to grow its global footprint
Canton Lucerne – Gestlich Pharma, the world market leader in regenerative dentistry, has acquired the Tennessee-based US medtech company: Lynch Biologics.
Geistlich Pharma and Lynch Biologics share a mission to advance new regenerative technologies in dentistry. The aim is to provide even better support for the healing of the body’s own bones and tissues. To this end, the two companies have now joined forces to foster research, education, quality and safety.
Lynch Biologics, like Geistlich, is committed to medical regeneration and with its advanced biotechnological solutions, the company has already been able to help numerous of patients restore lost bone or soft tissue. Its most popular and proven product is the GEM 21S® which utilizes a growth factor that is capable of accelerating the body’s own regeneration.
With this acquisition, Geistlich strengthens its position in the USA and can serve customers even more comprehensively with its regenerative portfolio.
“The acquisition of Lynch Biologics demonstrates our commitment to the US and further enhances our portfolio of innovative products used worldwide. Our two companies complement each other perfectly in terms of scientific focus and expertise in regeneration,” commented Dr. Ralf Halbach, CEO of Geistlich.
Geistlich expanding in Lucerne
Geistlich Pharma also announced that it would be expanding its research and production site in the canton of Lucerne. In the first stage, the international company will invest between 30 to 40 million Swiss francs in a new manufacturing and logistics building known as “The Hub”. Geistlich will create between 50 and 80 new jobs over the next five years.
“The Hub” will form the central building of the expansion and will be the largest building on the site when it is completed in 2026. This new manufacturing and logistics building will bring all cleanroom, packaging and logistics processes under one roof – activities that are currently performed in three buildings. Sustainability and planning in harmony with nature are important to Geistlich; therefore “The Hub” will be built as sustainable as possible.
Its location in Lucerne supplies high-quality biomaterials for medical regeneration to clinicians in over 90 countries.
About Geistlich Pharma
Geistlich Pharma AG develops, manufactures and markets medical products for restoring bone, cartilage and soft tissue as well as drugs. More than 750 employees worldwide work for Geistlich in the area of regenerative medicine. With its thirteen affiliates and 60 distribution partners, Geistlich’s medical devices and medicinal products reach around 90 markets worldwide.